Cancer Pain: Multidisciplinary Clinical Management

Pathophysiology

Cancer pain involves complex mechanisms reflecting the interaction between tumor, tissue microenvironment, and nervous system. Understanding these mechanisms is essential for choosing the right therapeutic strategy.

Somatic Nociceptive Pain

Results from nociceptor activation in somatic tissues — bones, muscles, joints, and skin — by direct tumor invasion. Bone metastasis pain is the classic example: tumor growth within bone activates osteoclasts, releases inflammatory mediators (prostaglandins, cytokines, nerve growth factor), and produces microfractures. The pain is typically localized, deep, and continuous, worsening with movement and weight-bearing.

Visceral Nociceptive Pain

Originates from distension, compression, or infiltration of abdominal or thoracic viscera. It is common in pancreatic, hepatic, and colon tumors. Visceral pain tends to be diffuse and poorly localized, often referred to distant dermatomes and accompanied by nausea, sweating, and autonomic reactions.

Neuropathic Pain

Occurs when the tumor invades or compresses peripheral nerves, nerve plexuses, or the spinal cord. It can also result from treatments — chemotherapy-induced peripheral neuropathy (CIPN) affects 30-70% of patients treated with taxanes, platinum compounds, or vinca alkaloids. Neuropathic pain manifests as burning, electric shock, tingling, or numbness, with a dermatomal or nerve-territory distribution.

Breakthrough Pain

These are transient intense-pain episodes that arise against a background of controlled baseline pain. They affect 40-80% of patients with cancer pain and may be spontaneous or triggered by specific activities (movement, cough, defecation). Breakthrough pain peaks in minutes and lasts 15 to 60 minutes, requiring rapid-onset rescue medication.

Symptoms

Cancer pain can present in varied ways, depending on tumor type, location, and mechanisms involved. Clinical evaluation should consider not only intensity but also the functional and emotional impact of pain.

Diagnosis

Cancer pain diagnosis is fundamentally clinical, based on detailed history, focused physical examination, and validated assessment scales. Correctly identifying the pain type (nociceptive, neuropathic, mixed) is essential to guide appropriate treatment.

The Visual Analog Scale (VAS) and the Numerical Pain Scale (0-10) are basic tools. For more complete evaluation, instruments such as the Brief Pain Inventory (BPI) assess intensity and functional impact, while the DN4 identifies the neuropathic component.

Multidimensional Evaluation

Beyond intensity, evaluation should include: pain location and radiation, aggravating and relieving factors, temporal pattern (continuous, intermittent, breakthrough), and impact on sleep, mood, and functional activities. The emotional component — anxiety, fear of death, depression — amplifies pain perception and should be addressed simultaneously.

Additional workup includes magnetic resonance imaging to evaluate tumor invasion of nerve structures, bone scintigraphy to map metastases, and electroneuromyography to document peripheral neuropathy. Periodic reassessment is mandatory, since cancer pain is dynamic and shifts with disease progression or treatment response.

Differential Diagnosis

Not all pain in a cancer patient is cancer pain. Distinguishing pain directly related to the tumor from pain caused by comorbidities, treatments, or independent conditions is essential.

Treatment

Cancer pain treatment follows principles established by the World Health Organization (WHO) since 1986, with the classic analgesic ladder. Although revolutionary in its time, the contemporary approach is more flexible, incorporating multimodal therapies and individualization of treatment.

The core principle is that adequate pain control is a right of the cancer patient and a therapeutic priority, aimed at minimizing suffering and preserving quality of life throughout treatment.

Opioids in Cancer Pain

Opioids remain the cornerstone of treatment for moderate-to-severe cancer pain. Oral morphine is the WHO reference opioid, but oxycodone, transdermal fentanyl, and methadone are equally valid alternatives. Titration should be individualized, starting at low doses with adjustments every 24-48 hours based on response.

The most common adverse effects include constipation (almost universal — requires preventive laxative), nausea (transient in the first days), drowsiness, and pruritus. Analgesic tolerance can occur, requiring opioid rotation. Physical dependence is expected with prolonged use, but addiction (compulsive use despite harm) is rare in an adequately monitored oncologic context.

Adjuvant Analgesics

Adjuvants are medications whose primary indication is not analgesia but that significantly contribute to pain control in specific situations. For neuropathic pain, gabapentin and pregabalin act on voltage-gated calcium channels, while duloxetine and amitriptyline modulate the descending inhibitory pain pathway.

Corticosteroids (dexamethasone) help in pain from nerve compression, peritumoral edema, and brain metastases. Bisphosphonates and denosumab reduce pain and skeletal events in bone metastases. Subanesthetic-dose ketamine is reserved for refractory pain with a central sensitization component.

Acupuncture as Treatment

Acupuncture is one of the integrative therapies with the strongest scientific evidence in oncology. Guidelines from the Society for Integrative Oncology (SIO), endorsed by the American Society of Clinical Oncology (ASCO), recommend acupuncture for pain management in patients with cancer, with moderate-to-strong recommendation grade.

Randomized clinical trials suggest acupuncture may reduce cancer pain intensity, lower opioid consumption, and improve function in selected patients, though effects vary across studies. One of the most relevant works — the IMPACT trial published in JAMA Oncology — compared acupuncture vs. massage in patients with advanced cancer and showed an acupuncture benefit in pain reduction, a finding that needs replication in other settings before becoming definitive evidence.

Beyond pain control, acupuncture simultaneously addresses other frequent symptoms in cancer patients — fatigue, insomnia, nausea, xerostomia (dry mouth from radiotherapy), and anxiety — delivering an overall improvement in quality of life that no single analgesic can provide.

Clinical Evidence

A meta-analysis published in Chinese Medicine (Ge et al., 2022) analyzed randomized clinical trials of acupuncture for cancer pain and concluded that acupuncture, as an adjunct to standard analgesic therapy, significantly reduces pain intensity and improves quality of life. He et al. (2020) in JAMA Oncology reviewed the clinical evidence and reinforced that acupuncture is a safe and effective intervention for pain in cancer patients.

Safety recommendations published by de Valois et al. (2024) in Supportive Care in Cancer establish that acupuncture can be performed safely even in immunosuppressed patients, those with thrombocytopenia, or those on anticoagulants, provided the medical acupuncturist takes specific precautions — such as avoiding lymphedema áreas, using superficial techniques in patients with low platelets, and maintaining strict asepsis.

Safety in Cancer Patients

Acupuncture performed by a qualified physician is safe in cancer patients but requires attention to specific precautions. In patients with thrombocytopenia (platelets < 50,000), superficial techniques are preferred and deep points avoided. In limbs with lymphedema or lymphedema risk (post-mastectomy, for example), needling should be avoided in that limb.

In severely neutropenic patients (neutrophils < 500), sessions should be postponed until hematologic recovery. Irradiated áreas with fragile skin should be avoided. Disposable needles and strict asepsis are mandatory. The medical acupuncturist should maintain close communication with the oncology team to coordinate treatment.

Prognosis

The prognosis for cancer pain control is generally favorable when treatment is multimodal and individualized. With the WHO analgesic ladder applied well and adjuvant therapies, 70-90% of patients achieve adequate pain control.

Factors that hinder control include: pure neuropathic pain (less opioid-responsive), frequent breakthrough pain, incidental pain (triggered by movement in bone metastases), unaddressed psychological suffering, and opioid tolerance. In these cases, acupuncture and interventional procedures become more important as complementary strategies.

Myths and Facts

When to Seek Medical Help